echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > This month the EU CHMP recommended 5 new drugs on the market! Includes Roche Xofluza, Samsung Onbevzi

    This month the EU CHMP recommended 5 new drugs on the market! Includes Roche Xofluza, Samsung Onbevzi

    • Last Update: 2020-11-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On November 14th the European Medicines Agency(EMA) Human Medicines Commission (CHMP) recommended approval of five drugs at its monthly meeting, one of which was approved after a re-examination and an extension of the approval of six drugs.
    , CHMP issued a non-recommendation after a review, and three companies withdrew their marketing applications.
    new drug actively recommended: Phesgo (pertuzumab/trastuzumab) for the treatment of early and metastasis HER2-positive breast cancer.
    this drug from Roche is a fixed dose of Pertuzumab (pertuzumab) and Herceptin (trastuzumab, trastuzumab) combined with hyaluronoidase (hyaluronidase) and used by subsurface injection.
    Roclanda (latanoprost/netarsudil) is used to reduce high eye pressure (IOP) in adult primary open-angle glazing or high eye pressure patients, who experience insufficient eye pressure reduction due to the single use of latatin or netarsudil.
    eye potion from Aerie Pharmaceuticals is currently called Rocklatan in the U.S. market.
    Xofluza (baloxavir-marboxil) to treat people 12 years of age and older with simple influenza.
    the oral antiviral drug from Roche is also recommended for influenza prevention treatment in people 12 years of age and older.
    Onbevzi, a biosimilar from Samsung Biotech, is a biosimilar of Roche Avastin (bevacizumab, Beva zhunitumab) for the treatment of colon, rectal, breast, non-small cell lung, renal cell carcinoma, ovarian epithelial cancer, fallopian tube cancer or primary peritonal cancer and cervical cancer.
    recommended after a retrout: Elzonris (tagraxofusp) is used to treat primary plasma cell-like synaptic cell tumors (BPDCN), regardless of whether the patient has previously received other medications.
    CHMP initially rejected an application from Menarini in July, and after a re-examination CHMP recommended that it be approved for listing for BPDCN patients in exceptional circumstances, their use should be restricted for patients who have not received any treatment.
    not recommended after retesting: Gamifant (emapalumab) is used to treat primary phagocytosis lymphocytosis (HLH) in children under 18 years of age.
    CHMP gave a negative opinion in July, but Swedish pharmaceutical company Swedish Orphan Biovitrum called for the decision to be reviewed.
    reassessing its application, CHMP confirmed earlier recommendations that the drug's research data were "insufficient" to conclude that the interferon γ blocking antibody was effective for HLH treatment.
    actively recommends drug extension therapy adaptation certificate: Anjin Kyprolis (carfilzomib) in combined use with daratumumab (Daremu monoantigen) and dexamisong, in ligandsan and dexamisong, or in a separate use with dexamysund, for use in adult multiple myeloma patients who have received at least one previous treatment.
    new drug forms and dosages of dabigatran etexilate (dabigatran etexilate) - 20 mg, 30 mg, 40 mg, 50 mg, 110 mg and 150 mg doses of coated particles, as well as oral solution powders and solvents at doses of 6.25 mg/mL.
    CHMP also supports the approval of the drug for the treatment of venous thromboembolism events (VPTs) and the prevention of VTE recurrence in pediatric patients from birth to children under 18 years of age, and proposes new taboos for use in adult patients with severe kidney damage and pediatric patients with eGFR less than 50 mL/min/1.73m2.
    ViiV Healthcare's integrated enzyme chain transfer inhibitor, Dolutegravir, is a dispersive tablet formulation that is used in association with other antiretroviral drugs to treat HIV-1 infections in pediatric patients who are at least 4 weeks old and weigh at least 3 kg.
    positive comments from CHMP also include the latest dosage recommendations for Tivicay film coating tablets for children 6 years of age and older weighing at least 14 kg.
    Chiesi Farmaceutici's Trimbow (beclometasone/formoterol/glycopyronium bromide, pyclomisone/formotro/Glon bromide) is used for maintenance therapy for asthma and is suitable for adults who have not been treated with long-acting beta-2-subject agonists and large doses of inhaled corticosteroids, as well as adults who have experienced one or more asthma worsens in the previous year.
    Bayer oral Xa factor inhibitor Xarelto (rivaroxaban, devasaban) is used to treat VTE and prevent the recurrence of VTE in children with VTE from birth to under 18 years of age, including catheter-related thrombosis, cerebral vein and sinus thrombosis.
    (UCB) Xyrem (sodium oxybate, sodium oxybate) is used to treat narcostic sleeping sickness in adolescents and children under 7 years of age.
    application: Santhera Pharmaceuticals withdrew a listing application on 28 October for the treatment of Duchenne-type muscular dystrophy.
    month, the company decided to halt the development of Puldysa, a drug that was shown to be ineffective in a Phase 3 clinical study of DMD patients.
    BioMarin Pharmaceutical withdrew its application for approval of Roctavian gene therapy for the treatment of patients with severe haemophilia A.
    said it could not provide the requested data to address "significant objections" from the regulator's High Therapeutics Committee over clinical findings "in the current process."
    the gene therapy was rejected by the FDA before it was withdrawn.
    Agios company Tibsovo (ivosidenib) is used to treat relapse or refractic acute myeloid leukemia with IDH1 mutations.
    announced in October that CMHP did not believe the data from its Phase 1 clinical study supported the positive benefits-risk balance of the proposed adaptation, and subsequently withdrew its application for approval for the drug.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.